Amarin granted nod to market fish oil pill
This article was originally published in Scrip
Executive Summary
After causing a rumpus last week when a staging website went live unexpectedly before Amarin got the official nod from the US FDA for an experimental fish oil pill, the firm revealed after the bell on 26 July that it had indeed been granted the OK to market the drug in the US under the brand name Vascepa.
You may also be interested in...
J.P. Morgan Stockwatch: No Substitute For M&A
Stock market reaction to the first day’s news from the 38th J.P. Morgan Healthcare conference in San Francisco was negative, probably because expectations for a continuation of December’s bumper M&A bonanza were too high.
'That's Huge, Folks': Amarin's Vascepa Cuts CV Risk By 25% On Top Of Statins
Cardiovascular outcomes data exceeded expectations for the fish oil pill, vindicating Amarin, which has fought long and hard for Vascepa's place in the CV disease prevention market. A filing based on REDUCE-IT is expected in early 2019.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.